Children's Oncology Group Chair's Grant

儿童肿瘤学组主席补助金

• 批准号: 7910955
• 负责人: GREGORY H REAMAN
• 金额: $ 72.09万
• 依托单位: NATIONAL CHILDHOOD CANCER FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-07 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7910955
• 关键词: Acute; Adolescent; Area; Biology; Cancer Biology; Caring; Child; Children' s Oncology Group; Classification; Clinical; Clinical Trials; Conduct Clinical Trials; Development; Diagnostic; Disease; Goals; Grant; Immune response; Infant; Investigation; Laboratories; Malignant Childhood Neoplasm; Malignant Neoplasms; Mission; Modification; Molecular; Molecular Target; Multi-Institutional Clinical Trial; Patients; Process; Quality of life; Research; Research Personnel; Resistance; Resources; Risk; Schedule; Subgroup; Surgical Management; Survival Rate; Therapeutic; Therapeutic Intervention; Translating; Validation; base; cancer prevention; cancer type; conventional therapy; design; drug development; evidence base; improved; prevent; survivorship; young adult

During the past four decades, survival rates and cure for childhood cancer have improved dramatically. Previously a nearly uniformly fatal disease when not amenable to surgical management alone, cancer is now curable in the majority of children. This improvement is a direct result of the collaborative efforts of clinical and laboratory investigators in the context of cooperative, multi-center clinical trials. Further significant improvements in overall survival have been recently attained in some specific pediatric cancers. However, improvement has not been observed in all diagnostic types of childhood cancer. Recognizing the need to accelerate progress despite the difficulties encountered with limited patient numbers and constrained resources, the Children's Oncology Group (COG) successfully elected to unify its efforts to develop a coordinated and robust research agenda without sacrificing the progress that had resulted from previous competitive strategies in specific disease areas. Major refinements in risk classification based on expanded understanding of disease and host biology in larger numbers of patients have resulted from these efforts. Refinements in the definition of risk groups and increasing subgroups of patients and rare cancer types necessitate even more cooperation. Therapeutic intensification from augmentation of conventional agents and schedule modification is unlikely to result in further improvement, providing a compelling justification and emergent need to enhance correlative biologic investigation and accelerate the process of identification and validation of molecular targets in specific pediatric cancers. Moreover, incremental progress requires that pediatric cancer clinical investigation fully exploit evolving developments in molecular cancer therapeutics in a more rapid drug development paradigm than heretofore utilized for childhood cancer, especially for those types resistant to conventional therapies; this is also required to reduce the potential for significant acute and long-term sequelae associated with current therapy. In order to achieve its mission to cure and prevent childhood cancer, the COG will design and conduct clinical trials that will continue to define evidence-based care standards, conduct laboratory investigations into cancer biology and variability in host response to treatment and translate these findings into new,more effective and less toxic treatments. We will identify causes of childhood cancer and develop strategies aimed at cancer prevention. Finally, we will evaluate therapeutic interventions with a goal of improving the quality of life and survivorship in infant, children, adolescents and young adults with cancer.

在过去的四十年中，儿童癌症的存活率和治愈率显着改善。 以前，如果仅由手术治疗不适合，癌症现在是几乎统一的致命疾病，现在是 在大多数儿童中可以治愈。这种改进是临床合作努力的直接结果 和实验室研究人员在合作，多中心临床试验的背景下。进一步的意义 最近在某些特定的儿科癌症中获得了总体生存的改善。然而， 在所有诊断性的儿童癌症类型中尚未观察到改善。认识到需要 尽管患者人数有限，并且受到限制，尽管遇到困难 资源，儿童肿瘤学小组（COG）成功地选择了统一其发展的努力 协调和强大的研究议程而没有牺牲先前的进展 特定疾病领域的竞争策略。基于扩展的风险分类的主要改进 对疾病和宿主生物学的理解是由于这些努力而导致的。 风险群体的定义和越来越多的患者亚组和稀有癌症的细化 需要更多的合作。扩大常规代理和 时间表修改不太可能导致进一步改进，提供了令人信服的理由和 紧急需要增强相关生物学研究并加速识别过程和 在特定的儿科癌症中验证分子靶标。而且，增量进度要求 小儿癌临床研究完全利用分子癌治疗中不断发展的发展 与迄今为止用于儿童癌症的药物开发范式更快，特别是对于那些 耐药类型的类型；这也需要减少明显急性的潜力和 与当前治疗相关的长期后遗症。为了实现治愈和防止的使命 儿童癌症，COG将设计和进行临床试验，以继续定义循证 护理标准，对癌症生物学的实验室调查以及宿主对 治疗并将这些发现转化为新的，更有效和毒性更少的治疗方法。我们将确定 儿童癌症的原因并制定了针对预防癌症的策略。最后，我们将评估 治疗性干预措施的目的是改善婴儿，儿童的生活质量和生存质量 青少年和癌症的年轻人。